Nov. 21, 2019: Zydus Cadila has received the final approval from the USFDA for marketing Isosorbide Dinitrate Tablets USP ( 5 mg, 10 mg, 20 mg, 30 mg and 40 mg) to prevent attacks of Angina (chest pain).
These tablets dilate blood vessels, increases blood flow through to the heart. These will be manufactured at the group’s formulations manufacturing facility at Baddi. The group also received the final approval for Desonide Cream (US RLD – Desonide Cream), 0.05%.
The drug is a mild corticosteroid, used to treat a multiplicity of skin conditions (e.g., eczema, allergies, dermatitis, rash)in order to reduce swelling, itching and redness. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad. https://zyduscadila.com/public/pdf/pressrelease/Zydus_receives_final_approvals_from_the_USFDA_for_Isosorbide_Dinitrate_Tablets_and_Desonide_Cream.pdf